Phase 1/2 Study of FOG-001, a First-in-class Direct Β-Catenin:Tcf Inhibitor, in Patients with Colorectal Cancer, Hepatocellular Carcinoma, and Other Locally Advanced or Metastatic Solid Tumors.
Journal of Clinical Oncology(2025)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined